Patents by Inventor Zhigang Xiong

Zhigang Xiong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10370376
    Abstract: The present invention relates to an amorphous form of Idelalisib and its methods of preparation. Using a Cu-K? radiation, the X-ray powder diffraction (XRPD) pattern does not contain sharp diffraction peaks at a diffraction angle expressed in degrees 2?, and the X-ray powder diffraction pattern is shown in FIG. 1. The present invention also provides a preparation method for the amorphous form of Idelalisib. The amorphous form of Idelalisib of the present invention increases the solubility of Idelalisib and improves bioavailability of the drug product. As compared to the existing crystalline forms of Idelalisib, its solubility increases significantly, which improves body's absorption of the drug and makes it more efficacious in the clinical therapeutic treatment of diseases. Under the stress test conditions, the amorphous material can maintain good physical and chemical stabilities. The preparation method of amorphous Idelalisib according to the present invention is simple to operate and easy to implement.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: August 6, 2019
    Assignee: Alnova Pharmaceuticals, Ltd.
    Inventors: Xini Zhang, Zhigang Xiong, Tao Hu
  • Patent number: 10336796
    Abstract: A system, including methods and compositions, for treatment of ischemia.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: July 2, 2019
    Assignee: MOREHOUSE SCHOOL OF MEDICINE
    Inventors: Roger P. Simon, Zhigang Xiong
  • Patent number: 10201539
    Abstract: This application discloses a composition comprising an amiloride and/or an amiloride analog which can be used for reducing nerve injury or nervous system injury in a subject. The formulation of such composition is also disclosed. The application further directs to methods for treating nerve injury or nervous system injury by administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising amiloride, an amiloride analog or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: February 12, 2019
    Assignee: MOREHOUSE SCHOOL OF MEDICINE
    Inventors: Zhigang Xiong, Roger P. Simon
  • Publication number: 20180360829
    Abstract: A composition and method for preventing or reducing the incidence of a transient ischemic attack in a subject at risk for developing a stroke comprises orally administering to the subject a prophylactically effective amount of a pharmaceutical composition comprising an ASIC1a inhibitor capable of penetrating the blood-brain barrier. Preferred ASIC1a inhibitors for use in the disclosed methods include amiloride and amiloride analogs.
    Type: Application
    Filed: August 28, 2018
    Publication date: December 20, 2018
    Inventors: Zhigang Xiong, Roger P. Simon
  • Patent number: 10028951
    Abstract: This application discloses a composition comprising an amiloride and/or an amiloride analog which can be used for reducing nerve injury or nervous system injury in a subject. The formulation of such composition is also disclosed. The application further directs to methods for treating nerve injury or nervous system injury by administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising amiloride, an amiloride analog or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: July 24, 2018
    Assignee: MOREHOUSE SCHOOL OF MEDICINE
    Inventors: Zhigang Xiong, Roger P. Simon
  • Publication number: 20180193334
    Abstract: Provided are a pharmaceutical composition of an amorphous vortioxetine or a salt thereof, and a preparation method therefor. The pharmaceutical composition comprises an amorphous vortioxetine or a pharmaceutically acceptable salt thereof and two or more pharmaceutical excipients. The pharmaceutical composition has good stability and dispersity, and enhances the dissolution of vortioxetine or the pharmaceutically acceptable salt thereof, thereby improving the bioavailability of the medicinal formulation and the body absorption of the medicine.
    Type: Application
    Filed: March 7, 2018
    Publication date: July 12, 2018
    Applicants: Changzhou Fangnan Pharmaceuticals, Ltd., Changzhou Ainuoxinrui Pharmaceuticals, Ltd.
    Inventors: Xini Zhang, Zhigang Xiong
  • Patent number: 10016416
    Abstract: This application discloses a composition comprising an amiloride and/or an amiloride analog which can be used for reducing nerve injury or nervous system injury in a subject. The formulation of such composition is also disclosed. The application further directs to methods for treating nerve injury or nervous system injury by administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising amiloride, an amiloride analog or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: July 10, 2018
    Assignee: MOREHOUSE SCHOOL OF MEDICINE
    Inventors: Zhigang Xiong, Roger P. Simon
  • Publication number: 20180037584
    Abstract: The present invention relates to an amorphous form of Idelalisib and its methods of preparation. Using a Cu-K? radiation, the X-ray powder diffraction (XRPD) pattern does not contain sharp diffraction peaks at a diffraction angle expressed in degrees 2?, and the X-ray powder diffraction pattern is shown in FIG. 1. The present invention also provides a preparation method for the amorphous form of Idelalisib. The amorphous form of Idelalisib of the present invention increases the solubility of Idelalisib and improves bioavailability of the drug product. As compared to the existing crystalline forms of Idelalisib, its solubility increases significantly, which improves body's absorption of the drug and makes it more efficacious in the clinical therapeutic treatment of diseases. Under the stress test conditions, the amorphous material can maintain good physical and chemical stabilities. The preparation method of amorphous Idelalisib according to the present invention is simple to operate and easy to implement.
    Type: Application
    Filed: October 13, 2017
    Publication date: February 8, 2018
    Applicant: Alnova Pharmaceuticals, Ltd.
    Inventors: Xini Zhang, Zhigang Xiong, Tao Hu
  • Publication number: 20170342116
    Abstract: A system, including methods and compositions, for treatment of ischemia.
    Type: Application
    Filed: June 30, 2017
    Publication date: November 30, 2017
    Inventors: Roger P. Simon, Zhigang Xiong
  • Publication number: 20170202834
    Abstract: This application discloses a composition comprising an amiloride and/or an amiloride analog which can be used for reducing nerve injury or nervous system injury in a subject. The formulation of such composition is also disclosed. The application further directs to methods for treating nerve injury or nervous system injury by administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising amiloride, an amiloride analog or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 30, 2017
    Publication date: July 20, 2017
    Inventors: Zhigang XIONG, Roger P. Simon
  • Publication number: 20170182041
    Abstract: This application discloses a composition comprising an amiloride and/or an amiloride analog which can be used for reducing nerve injury or nervous system injury in a subject. The formulation of such composition is also disclosed. The application further directs to methods for treating nerve injury or nervous system injury by administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising amiloride, an amiloride analog or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 28, 2017
    Publication date: June 29, 2017
    Inventors: Zhigang XIONG, Roger P. SIMON
  • Patent number: 9629838
    Abstract: This application discloses a composition comprising an amiloride and/or an amiloride analog which can be used for reducing nerve injury or nervous system injury in a subject. The formulation of such composition is also disclosed. The application further directs to methods for treating nerve injury or nervous system injury by administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising amiloride, an amiloride analog or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 21, 2013
    Date of Patent: April 25, 2017
    Assignee: MOREHOUSE SCHOOL OF MEDICINE
    Inventors: Zhigang Xiong, Roger P. Simon
  • Publication number: 20160271128
    Abstract: This application discloses a composition comprising an amiloride and/or an amiloride analog which can be used for reducing nerve injury or nervous system injury in a subject. The formulation of such composition is also disclosed. The application further directs to methods for treating nerve injury or nervous system injury by administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising amiloride, an amiloride analog or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 19, 2015
    Publication date: September 22, 2016
    Inventors: Zhigang XIONG, Roger P. SIMON
  • Publication number: 20160184304
    Abstract: This application discloses a composition comprising an amiloride and/or an amiloride analog which can be used for reducing nerve injury or nervous system injury in a subject. The formulation of such composition is also disclosed. The application further directs to methods for treating nerve injury or nervous system injury by administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising amiloride, an amiloride analog or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 19, 2016
    Publication date: June 30, 2016
    Inventors: ZHIGANG XIONG, ROGER P. SIMON
  • Publication number: 20160143908
    Abstract: This application discloses a composition comprising an amiloride and/or an amiloride analog which can be used for reducing nerve injury or nervous system injury in a subject. The formulation of such composition is also disclosed. The application further directs to methods for treating nerve injury or nervous system injury by administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising amiloride, an amiloride analog or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 19, 2015
    Publication date: May 26, 2016
    Inventors: Zhigang XIONG, Roger P. Simon
  • Publication number: 20140011817
    Abstract: This application discloses a composition comprising an amiloride and/or an amiloride analog which can be used for reducing nerve injury or nervous system injury in a subject. The formulation of such composition is also disclosed. The application further directs to methods for treating nerve injury or nervous system injury by administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising amiloride, an amiloride analog or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 21, 2013
    Publication date: January 9, 2014
    Applicant: Morehouse School of Medicine
    Inventors: Zhigang Xiong, Roger P. Simon
  • Patent number: 7892764
    Abstract: Systems, including methods and compositions, for seizure suppression, such as inhibition of epileptic seizures. In some embodiments, the methods may provide a screen for anti-seizure drugs. One or more compositions may be selected based on an ability to affect a response of biological cells to a change in extracellular pH and/or to affect an activity of at least one acid sensing ion channel (ASIC). Based on the one or more compositions selected, at least one drug candidate may be assayed for inhibition of seizure-like electrical activity and/or seizures. In some embodiments, the methods and compositions may, respectively, administer and provide an effective amount of PcTX1, a peptide derivative of PcTX1 amiloride, an amiloride derivative, or a combination thereof to a subject prone to seizures and/or having a seizure, in order to suppress seizure activity.
    Type: Grant
    Filed: November 21, 2007
    Date of Patent: February 22, 2011
    Assignee: Legacy Emanuel Hospital & Health Center
    Inventors: Zhigang Xiong, Roger P. Simon
  • Publication number: 20080242588
    Abstract: Systems, including methods and compositions, for seizure suppression, such as inhibition of epileptic seizures. In some embodiments, the methods may provide a screen for anti-seizure drugs. One or more compositions may be selected based on an ability to affect a response of biological cells to a change in extracellular pH and/or to affect an activity of at least one acid sensing ion channel (ASIC). Based on the one or more compositions selected, at least one drug candidate may be assayed for inhibition of seizure-like electrical activity and/or seizures. In some embodiments, the methods and compositions may, respectively, administer and provide an effective amount of PcTX1, a peptide derivative of PcTX1 amiloride, an amiloride derivative, or a combination thereof to a subject prone to seizures and/or having a seizure, in order to suppress seizure activity.
    Type: Application
    Filed: November 21, 2007
    Publication date: October 2, 2008
    Applicant: Legacy Emanuel Hospital & Health Center
    Inventors: Zhigang Xiong, Roger P. Simon